SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid high trading volume and community excitement, with some investors anticipating significant catalysts in the near future, possibly driven by speculation around new partnerships. Community members are pointing to the high short interest, hinting at a potential squeeze, while also highlighting the company's potential for growth in the eVTOL sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the implications of its AI spending and recent moves into private debt markets, drawing comparisons to pre-2008 financial tactics. Community discussion revolves around the stock's volatility and whether its pullback represents a buying opportunity or reflects deeper concerns about AI investments. Some are pointing to potential data center deals as a possible catalyst.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending due to a sharp decline in its stock price, sparking community concern and speculation about the reasons behind it, including the potential impact of the DVLT deal and the company's leadership. Some investors are questioning the company's direction, while others are anticipating a potential short squeeze or positive news to reverse the current trend. Discussions also involve the possibility of a strategic play related to Semnur and its valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

TDOC is trending as community members discuss its potential for a short squeeze, citing high short interest and upcoming catalysts. Bullish sentiment is fueled by mentions of technical indicators, such as breaking above key moving averages, and speculation around potential AI integration and partnerships. Some investors express frustration with the stock's historical performance and management, while others remain optimistic about its long-term growth potential in the telehealth sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in BCRX Stock?

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Pharmaceuticals, Inc. (BCRX) is now looking forward to data on its Netherton Syndrome and DME pipeline programs after its second-quarter earnings beat Wall Street expectations on the strong performance of its Orladeyo drug.“Our Netherton Syndrome and DME (diabetic macular edema) pipeline programs remain on track to have some data by the end of the year,” said CEO Jon Stonehouse on the company’s earnings call on Monday. The company is enrolling patients for an early-stage trial of both investigational drugs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_11_07_20_AM_png_98d2936188.webp" alt="BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock’s fair valuation is double its current level.<stembedurl>https://stocktwits.com/doublebtx/message/623619202</stembedurl>Another expressed disappointment at the stock’s slow rally.<stembedurl>https://stocktwits.com/coleslaugh/message/623622668</stembedurl>Netherton syndrome is a rare genetic disorder primarily affecting the skin, hair, and immune system, in which patients experience severe skin problems, including redness, scaling, and blistering, as well as hair abnormalities like bamboo hair.DME, meanwhile, is a leading cause of vision loss in people with diabetes. Fluid accumulates in the central part of the eye’s retina, causing swelling and blurry or distorted vision.A company spokesperson said on the call that the firm is looking at data on several endpoints, including the penetration of the drug in the skin, and on potential efficacy endpoints, including itching and healing of the skin with its investigational drug for Netherton syndrome. For the company’s investigational drug for DME, the company is looking at the effect of the drug on the retina and the potential for reducing the swelling in the retina after a dose of the drug.For the second quarter, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-second-quarter-2025-financial-results-and">reported</a> total revenue of $163.35 million, compared to $109.33 million in the corresponding quarter of 2024, and above an analyst estimate of $149.22&nbsp;&nbsp;&nbsp;&nbsp;million, as per data from Fiscal AI.Orladeyo, the company’s medicine used to prevent attacks of hereditary angioedema (HAE), accounted for a whopping 96% of the company’s total revenue in the quarter. Orladeyo's net revenue in the quarter jumped 45% to $156.8 million.For the full year, the company now expects global net Orladeyo revenue to be between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business. Biocryst in June said that it has entered into a definitive agreement to sell its European Orladeyo business to Neopharmed Gentili for up to $264 million. Closing of the transaction is expected by early October.The company said that it also remains on track to deliver net income and positive cash flows for the full year 2025.BCRX stock is up by about 12% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-announces-purchase-of-blade-urban-air-mobility-business/chrXN6wRdTY">Joby Aviation Stock Flies 15% After Company Announces Purchase Of Blade’s Urban Air Mobility Business: Retail’s Not Entirely Convinced</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level

CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 

Equity

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts 

ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes. 

Select Medical Expands Presence in Tennessee With Ballad Health Deal

SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses. 

BioCryst Pharmaceuticals, Inc. (BCRX) on Friday said that it has entered into a definitive agreement to sell its European Orladeyo business to Italian pharmaceutical company Neopharmed Gentili for up to $264 million.BCRX shares were up by over 4% in the pre-market session, following the news.As per the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-sale-european-orladeyor-berotralstat-business">agreement</a>, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo. Biocryst is also eligible to receive up to $14 million in future milestone payments.Orladeyo, also known as berotralstat, is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children 12 years of age and older. Hereditary angioedema (HAE) is a rare genetic disorder causing recurring episodes of severe swelling in various body parts, including the limbs, face, intestinal tract, and airway.<a href="https://stocktwits.com/symbol/BCRX">BioCryst</a> plans to use the proceeds from the transaction to retire all remaining term debt of $249 million from Pharmakon, which will eliminate approximately $70 million of future interest payments.The biotech company expects the transaction to result in at least $50 million in expected annual operating expense savings for BioCryst. It also expects to end 2027 with approximately $700 million in cash and no term debt, marking an increase of $400 million from its previous 2027 net cash guidance.In the first quarter (Q1) of 2025, BioCryst reported Orladeyo net revenue of $134.2 million, marking a growth of 51% year-on-year. Oraledyo revenue, in fact, accounted for about 92% of the company’s overall revenue in the period.However, sales from the U.S. contributed 89.5% of global Orladeyo net revenues in the first quarter, implying the European business accounted for only a small portion.On Stocktwits, retail sentiment around BCRX stayed unchanged within ‘bearish’ territory over the past 24 hours, accompanied by ‘low’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1250/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_7_45_04_AM_png_68794667d1.webp" alt="BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits" width="1250" height="134"><figcaption>BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure>However, a Stocktwits user expressed surprise at the deal and opined that the additional cash makes it easier for the company to find a buyer if that is what it intends to do.<stembedurl>https://stocktwits.com/justfkntrade/message/619211689</stembedurl>Another opined that the deal makes the company an ‘irresistible candy’ with no debt.<stembedurl>https://stocktwits.com/gdesivir/message/619209736</stembedurl>Biocryst had also said in May that it expects to be profitable for the full year 2025, a year ahead of schedule.BCRX stock is up by 28% this year and by about 58% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-slams-eu-as-closed-for-business-after-200-m-fine-warning-of-daily-penalties/chmguP6RRIt">Meta Slams EU As ‘Closed For Business’ After $200M Fine, Warning of Daily Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish

As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up to $14 million in future milestone payments.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCRX News

BCRX Biocryst Pharmaceuticals Inc.